Global mergers and acquisitions activity is accelerating toward a historic inflection point. Morgan Stanley projects that deal volumes will reach a record $6.4 trillion in 2026, a figure that would surpass previous peaks and signal a structural — not merely cyclical — resurgence in corporate dealmaking. For CFOs, General Counsel, and M&A Directors navigating this environment, three concurrent deal streams are defining the landscape: cross-border strategic buyouts in energy and infrastructure, large-cap consolidation in life sciences and industrial technology, and tightening regulatory scrutiny at both federal and state levels.

Cross-Border Transactions: Energy and Life Sciences Set the Tone

Two headline transactions illustrate the breadth and ambition of current cross-border deal activity. First, EDF has agreed to sell EDF Power Solutions — its U.S. and Canadian operations — to KKR, in a transaction that reflects both the strategic rationalization of European energy majors and the sustained appetite of private equity for North American infrastructure and renewable assets. For European corporates with transatlantic footprints, this deal is a reference point: asset carve-outs in regulated sectors require meticulous structuring around CFIUS review, FERC approvals, and provincial regulatory regimes in Canada.

Second, Merck KGaA has announced the acquisition of Bio-Techne for $11.3 billion — its largest transaction in over a decade — targeting life sciences tools critical to drug research and biomanufacturing. This deal underscores the continued willingness of European strategics to deploy significant capital into U.S. targets where proprietary technology and platform scale justify premium valuations. Cross-border due diligence in life sciences must now account for evolving U.S. export controls on biotechnology, in addition to standard HSR filings and foreign direct investment screening.

Semiconductor Consolidation and the AI Infrastructure Thesis

The $7 billion all-stock acquisition of Synaptics by ON Semiconductor is a defining moment for the semiconductor sector’s ongoing consolidation around artificial intelligence-enabled devices and physical AI applications. All-stock structures of this scale reflect both confidence in combined entity valuations and a pragmatic approach to preserving cash for post-merger integration investment. For dealmakers in industrial technology and semiconductors, the strategic logic is clear: scale in AI-adjacent hardware is becoming a prerequisite for competitive relevance, and organic growth alone cannot deliver it at the required pace.

This transaction also highlights a broader theme in corporate finance: the convergence of AI, data center infrastructure, and hardware is driving a new wave of consolidation that cuts across traditional sector boundaries. M&A Directors evaluating targets in this space should stress-test synergy assumptions against rapidly shifting technology roadmaps and assess whether target IP portfolios are defensible under current U.S. and EU semiconductor export control regimes.

Regulatory Headwinds: State-Level Scrutiny Adds Complexity

While federal antitrust enforcement remains a primary concern for large-cap transactions, a quieter but consequential shift is occurring at the state level. Maine has enacted new competition laws introducing notice and approval requirements for certain healthcare transactions — a development reported by Law360 that reflects a growing trend of sub-federal regulatory activism. For private equity-backed platforms executing buy-and-build strategies in healthcare, this creates a fragmented compliance map that demands early legal assessment in deal structuring.

European acquirers entering U.S. healthcare markets should note that state-level review timelines can materially affect deal certainty and closing schedules. Integrating state regulatory milestones into transaction timetables — alongside FTC and DOJ review — is no longer optional; it is a baseline requirement for credible deal execution.

Implications for Decision-Makers

  • Accelerate pre-deal regulatory mapping: In cross-border transactions spanning energy, healthcare, and semiconductors, multi-jurisdictional regulatory risk must be assessed at the term sheet stage, not post-signing.
  • Revalue post-merger integration planning: As deal volumes rise and competition for quality assets intensifies, differentiated integration capability — particularly in technology and talent retention — is a direct driver of value creation.
  • Stress-test AI-driven synergy assumptions: Deals premised on AI and data infrastructure convergence carry technology execution risk that standard financial due diligence does not fully capture. Technical and operational diligence must be elevated accordingly.
  • Monitor state-level healthcare regulation proactively: Maine’s new framework may be a leading indicator. Private equity sponsors and strategic acquirers in healthcare should track legislative developments across key states as part of ongoing portfolio management.

Key Takeaway

The convergence of record-projected deal volumes, large-scale cross-border transactions, and a more complex regulatory environment means that execution quality — not just deal origination — will determine outcomes in 2025 and 2026. Boards and executive teams that invest now in robust due diligence frameworks, multi-jurisdictional regulatory intelligence, and disciplined post-merger integration capabilities will be structurally better positioned to capture value as global M&A activity reaches its next peak.